Literature DB >> 15969931

Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.

Toshiyuki Sakaeda1, Koichi Iwaki, Mikio Kakumoto, Mika Nishikawa, Toshiro Niwa, Jiang-shu Jin, Tsutomu Nakamura, Kohshi Nishiguchi, Noboru Okamura, Katsuhiko Okumura.   

Abstract

The effects of micafungin on cytochrome P450 3A4 (CYP3A4) metabolic and multidrug resistance protein 1 (MDR1) transport activities were investigated and compared with those of amphotericin B and four azole antifungal drugs (ketoconazole, itraconazole, fluconazole and miconazole). The effects on the metabolic activity of CYP3A4 were examined by measuring nifedipine oxidase activity in human liver microsomes and the effects on MDR1 transport activity were evaluated using [3H]digoxin in MDR1-overexpressing LLC-GA5-COL150 cells. An inhibitory effect on CYP3A4 activity was found for ketoconazole, itraconazole and miconazole, with 50% inhibitory concentrations of 11.7, 32.6 and 74.2 nM, respectively. Fluconazole and micafungin had only slight inhibitory effects and amphotericin B had no effect. The MDR1-mediated transport of [3H]digoxin was inhibited by ketoconazole and itraconazole, and slightly by miconazole. It is suggested that micafungin and amphotericin B would be unlikely to cause drug-drug interactions by inhibition of CYP3A4 and MDR1. A positive correlation between the inhibitory effects on CYP3A4 and MDR1 activities was observed, and the physicochemical mechanisms involved and impact on clinical treatment should be studied further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969931     DOI: 10.1211/0022357056118

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  20 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

2.  Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.

Authors:  Mia Birkhøj Kjærstad; Flemming Nielsen; Lene Nøhr-Jensen; Stine Zwisler; Kim Brøsen; Helle Raun Andersen
Journal:  Eur J Clin Pharmacol       Date:  2010-10-06       Impact factor: 2.953

Review 3.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics.

Authors:  Dominique A Ramirez; Keagan P Collins; Allister E Aradi; Katherine A Conger; Daniel L Gustafson
Journal:  Drug Metab Dispos       Date:  2018-12-19       Impact factor: 3.922

Review 5.  Safety of micafungin in infants: insights into optimal dosing.

Authors:  Simon Ascher; Phillip Brian Smith; Daniel K Benjamin
Journal:  Expert Opin Drug Saf       Date:  2011-01-13       Impact factor: 4.250

6.  A review of clinical experience with newer antifungals in children.

Authors:  Renee M Fallon; Jennifer E Girotto
Journal:  J Pediatr Pharmacol Ther       Date:  2008-07

7.  In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.

Authors:  Ji-Qin Wu; Kun Shao; Xuan Wang; Rui-Ying Wang; Ya-Hui Cao; Yun-Qiu Yu; Jin-Ning Lou; Yan-Qiong Chen; Hua-Zhen Zhao; Qiang-Qiang Zhang; Xin-Hua Weng; Chen Jiang; Li-Ping Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

8.  Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.

Authors:  Kimitaka Suetsugu; Hiroaki Ikesue; Toshihiro Miyamoto; Motoaki Shiratsuchi; Nanae Yamamoto-Taguchi; Yuichi Tsuchiya; Kumi Matsukawa; Mayako Uchida; Hiroyuki Watanabe; Koichi Akashi; Satohiro Masuda
Journal:  Int J Hematol       Date:  2016-11-07       Impact factor: 2.490

9.  Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats.

Authors:  Fumie Abe; Jun Ueyama; Noriyo Kawasumi; Masayuki Nadai; Tamon Hayashi; Miki Kato; Masafumi Ohnishi; Hiroko Saito; Naoshi Takeyama; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 10.  Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

Authors:  Sarah A Cross; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.